Mohammad Alabbas, MD, discusses a matched real-world comparison of elafibranor and seladelpar in PBC, including 1-year outcomes and limitations for treatment selection.
Mohammad Alabbas, MD
Advertisement
Research fellow at the hepatology section of the gastrointestinal department at the Cleveland Clinic.
Articles by Mohammad Alabbas, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Lp(a) HORIZON Shows Pelacarsen Lowers Lp(a) 78% But Not Cardiovascular Events
2
Cannabis Use Tied to Higher Odds of Stroke, Cardiovascular Disease
3
ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD
4
AHA 2026: Intensive Blood Pressure Control Reduces Events After Ischemic Stroke
5